Benzinga | Oct 15, 2021 09:22AM EDT

Stifel Maintains Buy on Biogen, Lowers Price Target to $344

Stifel analyst Paul Matteis maintains Biogen (NASDAQ:BIIB) with a Buy and lowers the price target from $430 to $344.